New drug cocktail shows promise for untreated leukemia patients
NCT ID NCT07514832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia (AML) who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve complete remission (cancer disappearance) after two cycles. The study involves 48 participants across multiple centers and tracks side effects and minimal residual disease (tiny leftover cancer cells).
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill tackle Tough-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can a triple-drug combination tame AML without intensive chemo?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- New Triple-Drug strategy aims to boost remission in Hard-to-Treat leukemia
- New drug cocktail aims to boost remission in tough AML cases